barrier can flood the CaP tissue microenvironment, allowing therapeutically significant levels at reduced systemic dosages. The tissue xenograft model provides a unique tool for analysis of the role of targeted microvascular damage in development of organ-specific therapies, and the role of a reconstituted human EC compartment in "acquired resistance".
INTRODUCTION AND OBJECTIVES: Macrophage inhibitory cytokine-1 (MIC-1) is a divergent member of the transforming growth factor-b family. We previously reported that high-fat diet (HFD) induced prostate cancer progression through the upregulation of MIC1 in cancer cells. Here, we investigated the role of MIC-1 in controlling tumor microenvironment in HFD-induced prostate cancer progression.
METHODS: PC-3M-luc-C6 cells were intraperitoneally injected into BALB/c-nu/nu mice, and equal numbers of mice were categorized into HFD and controlled diet (CD) groups. The extent of tumor burden was detected using the IVISÔ imaging system, and expression of MIC, proportion of stromal cells in tumors, serum level of MIC-1, and cytokine profile were examined. In vitro, functional analyses in PC-3 cells cultured with prostate stromal cell (PrSC) condition medium, recombinant MIC-1, and cytokine-blocking antibodies were performed. In humans, the relationship between serum level of MIC-1, MIC-1 expression in surgically resected prostate tissues, and clinicopathological parameters were assessed.
RESULTS: The mean luciferase activity in mice at 4 weeks was significantly higher in the HFD group than in the CD group (p < 0.01). In the HFD group, MIC-1 expression and alpha smooth muscle actin (aSMA)-positive cells significantly increased in tumors, and serum levels of MIC-1 and IL-8 were significantly elevated. In vitro, recombinant MIC-1 (rMIC-1) induced PrSCs to secrete proinflammatory cytokines, including IL-8 and IL-6, and activate ERK in addition to the directly stimulate cancer cell proliferation and invasion. PrSCs and rMIC-1 increased the invasive capacity of PC-3 cells; however, the effects were impaired by IL-6 and IL-8 capture antibody. Patients with high staining scores of aSMA had significantly higher stage tumors (¼pT2a) than those with low staining scores of aSMA (p ¼ 0.031), and the serum level of MIC-1 tended to be higher in patients with high staining scores of aSMA (p ¼ 0.056).
CONCLUSIONS: MIC-1 stimulates stromal cytokine production in HFD-induced prostate cancer progression. MIC-1 and tumor stromal microenvironment may have implications in the prevention and treatment of HFD-induced prostate cancer progression.
Source of Funding: None

MP29-15 MAKE IT FROM SCRATCH OR HAVE IT DELIVERED? SATISFYING THE FATTY ACID DEMAND OF PROSTATE CANCER
Sandra Gaston*, Boston, MA; Soroush Rais-Bahrami, Jeffrey Nix, Peter Kolettis, James Bryant, Birmingham, AL; James Kearns, Boston, MA; Oelschlager Denise, Dennis Otali, William Grizzle, Birmingham, AL INTRODUCTION AND OBJECTIVES: One of the hallmarks of the malignant phenotype is an increase in the cell's demand for fatty acids (FA). Many cancers, including prostate cancer (PrCa), show increased expression of fatty acid synthase (FASN), a multi-component enzyme that catalyzes the de novo synthesis of the FA palmitate. However recent observations suggest that alternate mechanisms for FA acquisition are also important, including the utilization of exogenous palmitate when it's available. Recently, through a biopsy-based molecular analysis of high risk PrCa, we identified a tumor subtype with very high (>10 fold) "outlier" overexpression of fatty acid binding protein 5 (FABP5). FABP5 is involved in lipid transport and signaling, and it facilitates the utilization of palmitate and other FAs from outside of the cell. De novo palmitate synthesis by the FASN pathway is energetically expensive compared to utilization of exogenous FAs. We propose that PrCas that can efficiently utilizes exogenous palmitate are at a selective advantage when dietary FAs are abundant. In this study, to test that hypothesis, we compared FABP5 and FASN expression levels in PrCas obtained from diagnostic biopsies from normal weight, overweight and obese study subjects.
METHODS: A total of 201 consecutive eligible prostate biopsy patients were prospectively enrolled; 151 (75%) of these patients were cancer positive. PrCa FABP5 and FASN mRNA expression were measured by qrtPCR and FABP5/FASN and FASN/FABP5 expression ratios were determined for each cancer positive core. BMI and selfidentified race were obtained from hospital records.
RESULTS: The expression of FABP5 and the FABP5/FASN expression ratio were significantly higher in overweight and obese individuals compared to normal weight individuals (mean FABP5/FASN overexpression ratio of 20.2 in overweight/obese subjects vs 4.0 in normal weight subjects; p < 0.05). The highest levels of PrCa FABP5 outlier overexpression (FABP5/FASN > 100) were observed in African American subjects with BMI > 30.
CONCLUSIONS: Our results are consistent with a growing body of evidence suggesting that the well-recognized "addiction" of PrCa for FA can be satisfied by more than one mechanism. In our study population, PrCa subtypes with high levels of FABP5 overexpression were more common in biopsy patients who were overweight or obese. Such FABP5 dominant PrCa subtypes may be more sensitive to dietary interventions than the more widely studied FASN dominant PrCas. METHODS: We employed a comprehensive approach using a panel of cell lines, in house tissue samples, publicly available large data sets such as TCGA, a series of in vitro assays such as quantitative-real time PCR; western blot; fluorescence-activated cell sorting assays for cell cycle distribution and apoptosis; assays for cell viability, migration and invasion assays. Luciferase reporter assays and in-vivo intra-cardiac study in nude mice was also performed.
RESULTS: The expression of miR-588 was significantly suppressed or silenced in prostate cancer tissue samples and cell lines when compared with normal tissues and a non-malignant cell line. Similar results were observed by analyzing the publicly available TCGA data sets for prostate adenocarcinoma. Functionally ectopic expression of miR-588 induced G0/G1 cell cycle arrest and apoptosis and suppressed cell proliferation. miR-588 exerted these functional effects by directly targeting the oncogenic Cyclin A2 that is involved in cancer cell cycle and proliferation. In silico algorithm showed a complimentary binding sequence in the 3'UTR of Cyclin A2 for miR-588. Vol. 199, No. 4S, Supplement, Saturday, May 19, 2018 THE JOURNAL OF UROLOGY â e371
